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Technically difficult echocardiographic studies with suboptimal images remain a signifi-
cant challenge in clinical practice despite advances in imaging technologies over the past
decades. Use of microbubble ultrasound contrast for left ventricular opacification and
enhancement of endocardial border detection during rest or stress echocardiography has
become an essential component of the operation of the modern echocardiography labo-
ratory. Contrast echocardiography has been demonstrated to improve diagnostic accuracy
and confidence across a range of indications including quantitative assessment of left
ventricular systolic function, wall motion analysis, and left ventricular structural abnor-
malities. Enhancement of Doppler signals and myocardial contrast echocardiography for
perfusion remain off-label uses. Implementation of a contrast protocol is feasible for most
laboratories and both physicians and sonographers will require training in contrast specific
imaging techniques for optimal use. Previous concerns regarding the safety of contrast
agents have since been addressed by more recent data supporting its excellent safety
profile and overall cost-effectiveness.
Copyright ª 2013, Cardiological Society of India. All rights reserved.1. Introduction Microbubble ultrasound contrast is now regarded as anTransthoracic echocardiography (TTE) remains a versatile and
globally themost commoncardiacdiagnostic imagingmodality.
Numerous developments in ultrasound technology, including
harmonic imaging and improvement in imaging frame rates up
to 120 frames per sec, have greatly enhanced the diagnostic ca-
pabilities of the technique. However, there is still a need to
improve image resolution when the acoustic windows are
limited and endocardial definition suboptimal. This may result
in potentially missed or incorrect diagnoses and consequential
adverse outcomes or further inappropriate downstream in-
vestigations with both temporal and financial implications.1hi).
2013, Cardiological Societessential tool in the day-to-day practice of the clinical echo-
cardiography laboratory to overcome some of these limita-
tions. The contemporary approved and appropriate
indications for the use of ultrasound contrast agents include
left ventricular opacification (LVO) and improvement of
endocardial border detection (EBD), when 2 contiguous
segments are not well-visualized without contrast
enhancement.2e4 Some research and off-label use of contrast
agents include augmentation of the spectral Doppler signal
and assessment of myocardial perfusion. While the latter
showed enormous potential in animal research studies, it has
not translated into everyday clinical practice.y of India. All rights reserved.
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graphic contrast agents are Sonovue (Bracco Imaging),
Optison (GE Healthcare) and Definity (Lantheus Medical Im-
aging) that is also marketed under the label of Luminity in
Europe. While they are essentially similar in the way they
enhance TTE image quality, each of these microbubble
contrast agents have their own characteristics, which will be
discussed later. Delivered intravenously, these microbubbles
are sufficiently small (<10 mm; red blood cells are w6e8 mm
for reference) to allow transpulmonary passage and there-
fore provide real-time imaging of blood flow through the
left-heart. These microbubbles use high-molecular weight
gases with low-solubility and the high elasticity shell to
reduce acoustic destruction and thereby maintain the
microbubble integrity (stability), prolong circulating time
(persistence) or contrast effect, and maximize the non-linear
contrast backscatter.5,6
The injected microbubbles provide multiple gaseliquid
interfaces within the blood pool and thereby significantly
increasing the backscatter of ultrasound waves from the
insonating beam.2,7 These microbubbles undergo asym-
metric oscillation (alternating compression and expansion
with inverse changes in radius and stiffness) within the
applied ultrasound field and essentially behave as non-
linear scatterers. Real-time assessment with ultrasound
contrast for LVO and improvement of EBD is conventionally
performed with low-MI (usually <0.2) harmonic imaging.
This reduces microbubble disruption, enhances the intra-
cavitary contrast intensity, allows subtraction or filtering of
linear tissue backscatter and minimizes tissue harmonics.8
The end result is enhancement of the endocardium that
forms the border between the darker myocardium and
bright intracavitary contrast.2. Clinical utility and indications
The current consensus indications for contrast LVO in resting
transthoracic echocardiography include (Table 1):Table 1 e Current approveda indications for contrast
echocardiography.
LV opacification during resting transthoracic echocardiography in
difficult-to-image patients for:
 Improvement of LV endocardial border definition (when 2
contiguous segment are not well-visualized)
 Improved accuracy and reproducibility of quantitative LVEF
 Definitive diagnosis of LV structural abnormalities including
apical thrombi, apical HCM, LV non-compaction, and
complications of myocardial infarction (i.e. LV aneurysms and
pseudoaneurysms)
LV opacification during stress echocardiography (when 2
contiguous segment are not well-visualized) to improve sensitivity
and accuracy of wall motion analysis for detection of myocardial
ischemia
a Doppler signal enhancement, myocardial perfusion, and use of
contrast echocardiography during interventional procedures are
currently regarded as off-label uses for echocardiographic contrast
agents.1) Improvement of left ventricular (LV) EBD,
2) Increased accuracy and reproducibility of ventricular
volumetric assessments,
3) Quantitative assessment of ejection fraction,
4) Enhanced diagnostic confidence for LV structural abnor-
malities (including but not limited to apical thrombus, non-
compaction and hypertrophic cardiomyopathy where
near-field clutter and artifacts are problematic),
5) Microbubble contrast is also clinically indicated in stress
echocardiography when 2 contiguous segments are not
well-visualized with the intent of improving interpretation
of wall motion abnormalities and diagnostic accuracy,9
6) Off-label use of microbubble contrast agents for MCE in
perfusion imaging and Doppler signal enhancement will
also be discussed briefly in this review.
2.1. Left ventricular structure and function
2.1.1. Quantification of left ventricular systolic function
Quantitative evaluation of LV systolic function in the form of
the LV ejection fraction (LVEF) is one cornerstone for the initial
diagnosis of heart failure and remains a significant prognos-
ticator of survival. Many currently used chemotherapeutic
agents have an increased risk of early or delayed cardiovas-
cular toxicities and regular surveillance of LVEF is a critical
part of continuing care.10 It has been repeatedly demonstrated
that contrast-enhanced echocardiography for LVO improves
LVEF correlation with radionuclide ventriculography and
cardiac magnetic resonance imaging (cMRI), and decreases
the overall intra- and interobserver variability.1,11e16
2.1.2. Endocardial border definition and wall motion
assessment (resting and stress echocardiography)
Up to 20% of routine transthoracic echocardiogramsmay have
poor EBD and could be regarded as non-diagnostic.1,17,18 Pa-
tient factors contributing to these difficult images include co-
existent chronic obstructive airways disease, chest wall-
deformities, and body habitus (obesity). Studies performed
in the emergency department or on mechanically ventilated
patients in the intensive care setting also pose significant
challenges from the perspective of image quality. Multiple
studies have demonstrated that microbubble contrast com-
binedwith harmonic imaging for LVO improves the diagnostic
accuracy, confidence and interobserver agreement in assess-
ment of regional systolic function or myocardial thickening in
these technically difficult-to-image patients.19e22 Kitzman et
al demonstrated that contrast-enhanced images resulted in
the conversion of 48% of non-diagnostic examinations
(defined as 4 of 6 non-evaluable segments in a single apical
view) into “salvaged” studies (where 1 poorly visualized
segment remained on the same comparative view) following
LVO.23 These salvage rates have been reported to be higher in
intensive care unit (ICU) patients who were mechanically
ventilated.24e26
The assessment of regional wall motion (segmental
myocardial thickening) that forms the basis of interpretation
of stress echocardiography is subjective and highly dependent
on optimal endocardial definition. The same patient factors
contributing to less than ideal images are often further exag-
gerated during stress. Technically suboptimal studies have
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(ESE) and the inter-institutional agreement (positive or nega-
tive) for dobutamine stress echocardiograms (DSE) ranges
from 43% with poor images to 100% in those with the highest
quality.27,28 Contrast administration enhances 77e95% of
poorly visualized segments during DSE and has been shown to
improve the diagnostic accuracy and readers’ interpretive
confidence.29e33
2.1.3. Delineation of left ventricular structural abnormalities
Despite the close anatomical position of the LV apex to the
ultrasound transducer “footprint” on the chest wall, the apical
region can be challenging to image due to foreshortening and
high prevalence of near-field artefacts. Contrast for LVO offers
significant advantages in visualizing the appearance of the
apex.
The accurate detection of an apical LV thrombus is critical
due to the potential for systemic embolization and devas-
tating outcomes. Standard non-contrast enhanced echocar-
diography may be non-diagnostic in a significant proportion
(up to 46% in one retrospective analysis) of patients and may
be difficult to distinguish from apical trabeculae, papillary
muscles, false tendons, tumors (albeit uncommon) or arte-
facts (clutter or reverberations).34 Contrast administration can
convert up to 90% of these suboptimal studies into diagnostic
images and anticoagulation therapy may then be initiated or
withdrawn as appropriate. Apical thrombi typically appear as
dark irregular intraluminal filling defects in comparison to the
relatively “smooth” ventricular endocardial border as outlined
by the bright intracavitary contrast (Figs. 1 and 2). Equally, the
addition of microbubble contrast to routine 2D harmonic im-
aging can rule out the presence of an apical thrombus, and
avoid unnecessary long-term anticoagulation (Fig. 3). Apical
aneurysms can also be clearly outlined and definitively diag-
nosed by LVO.
The differential diagnosis that needs to be delineated in-
cludes the aforementioned apical thrombi, apical tumors,
isolated left ventricular non-compaction, apical displacement
of the papillary muscles, and endomyocardial fibrosis. The
management decisions and prognosis for all these diagnoses
are very disparate. Contrast-enhanced echocardiography has
been demonstrated to establish the diagnosis of apical HCM
where routine imaging is unclear or non-diagnosticFig. 1 e Two-dimensional echocardiographic images from a stan
the LV apex. The non-contrast enhanced image demonstrates an
apical thrombus. Colour flow Doppler with a reduced scale was u
did not offer any significant additional diagnostic information.
defect void of any contrast infiltration consistent with a large L(Fig. 4).35,36 The classic end-diastolic “spade-like” appearance
of the LV apex on left ventriculography can be reproduced
non-invasively as an alternative to cMRI.37 Fig. 5 is an example
of contrast echocardiography revealing the appearance of
prominent trabeculae with deep recesses involving the apex
and mid-inferolateral walls typical of left ventricular non-
compaction.
LV pseudoaneurysms that occur as a result of a post-
myocardial infarction free wall rupture may be difficult to
distinguish from an aneurysm with underlying thinned and
scarredmyocardium. Echocardiographywill often identify the
echo-free collection but may encounter difficulty in localizing
the small neck or discontinuity in the myocardium (either by
2D, color or spectral Doppler) when the acoustic window or
images are suboptimal and potentially underestimate the true
maximal cavity diameter when thrombus is present. Given
the propensity of pseudoaneurysms for spontaneous fatal
rupture definitive diagnosis is critical to expedite surgical
intervention. Contrast LVO has been utilized and reported to
provide incremental diagnostic power to detect pseudoa-
neurysms as evidenced by direct visualization of contrast
extravasation through the narrow neck into the pericardial
space (Fig. 6).38e40
2.2. Off-label uses
2.2.1. Doppler signal enhancement
The peak tricuspid regurgitant (TR) jet velocity measured on
continuous wave Doppler analysis is used in the estimation of
the right ventricular systolic pressure. The degree of tricuspid
regurgitation does not directly correlate with the degree of
pulmonary hypertension. Trivial regurgitation can result in
incomplete Doppler spectral signals and an underestimation
of the true pressure gradient. Intravenous echo contrast can
be used to augment the TR envelope (defined as a smooth
parabolic well-defined signal) for more accurate assessment
of pulmonary pressures.41 Similarly, on the left side of the
heart, it can help improve the spectral Doppler assessment of
the peak aortic jet velocity.
2.2.2. Myocardial contrast echocardiography (MCE)
As the contrast microbubbles remain entirely in the intra-
vascular space and pass freely through the microcirculationdard apical 4-chamber view at a reduced depth to focus on
echodensity within the apex thatmay represent a possible
sed in an attempt to further delineate this echodensity but
Contrast enhancement clearly shows a large apical filling
V apical thrombus.
Fig. 2 e Technically difficult study with an aneurysmal apex on the non-contrast enhanced apical 2-chamber image.
Contrast administration then reveals a well-defined apical thrombus that would not have been detectable otherwise.
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described the method for quantification of MBF using a
continuous venous infusion ofmicrobubble contrast, followed
by destruction by exposure to high-intensity ultrasound pul-
ses, and then measuring the rate of replenishment and in-
tensity which is represented by a timeeintensity curve.42 The
rate of contrast reappearance calculated from the slope of the
timeeintensity curve is a measure of mean myocardial blood
flow velocity (ß) while the peak plateau intensity (A) repre-
sents the cross-sectional area of the microvasculature such
that A  ß equates to MBF.43 When there is hemodynamically
significant epicardial coronary artery stenosis with resultant
flow limitation that exceeds the distal compensatory micro-
vascular vasodilatation (coronary flow reserve), the rate and
intensity of contrast replenishment is reduced. Qualitative
visual assessment, which is the more common approach in
clinical applications of MCE, subjectively scores contrast
reappearance as normal (homogenous enhancement within
5 s following flash microbubble destruction at rest or within
2 s at stress) or reduced.43,44 Detailed discussion of quantita-
tive assessment of MBF is beyond the scope of the current
article.3. How to do it?
The 2008 American Society of Echocardiography consensus
statement on contrast agents in echocardiography advocatesFig. 3 e Two-dimensional echocardiographic apical 4-chamber
apical thrombus on the non-contrast enhanced image. The adm
the presence of an intraluminal filling defect and therefore avoa team approach for the successful introduction and imple-
mentation of contrast protocols into an echocardiography
laboratory.2 The team would primarily consist of the sonog-
rapher, physician echocardiographer and where available,
nursing staff who are competent and certified in obtaining
intravenous access and administration of intravenous
agents. Although there are no mandatory rules or legislations
governing the use of microbubble contrast agents, it is rec-
ommended that the sonographers be appropriately qualified
and credentialed in echocardiography and the responsible
physicians be independent and competent echocardiog-
raphers (minimum of ASE level 2 or equivalent training) with
skills in basic and advanced life support.45 This would form
the foundation to then develop an understanding of contrast
physics, indications for and contraindications to contrast
administration, and contrast-specific ultrasound imaging
techniques required to obtain optimal and diagnostic images.
Team members must also be prepared and equipped to deal
with patient adverse reactions associated with contrast use.
Clinical training and practical experience is crucial for both
sonographer and physician to become familiar with contrast
echocardiography. In the absence of formal training pro-
grams, a suitable means of acquiring the necessary practical
experience would be a preceptorship-type model that can be
undertaken at an established institution with a high-volume
of contrast studies and an adequate breadth of pathologies.
Table 3 provides a summary of the basic elements and
practical approach to setting up a contrast protocol.view demonstrating a dilated globular LV with a possible
inistration of intravenous echocontrast was able to exclude
iding unnecessary anticoagulation.
Fig. 4 e Two-dimensional non-contrast enhanced echocardiographic image suggestive of apical regional wall thickening
and then following injection of Definity echocontrast showing the typical spade-shape appearance of the LV apex as
described in apical HCM.
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The basic equipment required to set up a contrast injection
should be readily available in majority of echocardiography
laboratories. Essentially the same items used for an agitated
saline contrast study are required e syringes, sterile normal
saline for dilution and flushing, large guage needles for vial
venting and drawing up, intravenous cannulae, alcohol based
pads or swabs, gloves, three-way stopcock, gauze pads and
medical tape.46,47 A refrigerator for storage of the contrast
agents and the appropriate disposal containers for medical
sharps as per standard universal precautions will also be
necessary. Lastly, a fully-equipped resuscitation trolley with
emergency airway equipment, drugs required for advanced
life support, and an external defibrillator should bemandatory
in the event of a severe adverse reaction resulting in signifi-
cant cardio-respiratory compromise. This should already be
available, especially in laboratories where stress echocardio-
grams are being performed.
3.2. Patient identification
The sonographer has a key central role in implementing the
contrast protocol andmaintaining an efficient workflow. They
are at the first point of contact with the patient and therefore
allow early identification of a technically difficult study where
contrast enhancement will improve the diagnostic yield.Fig. 5 e Non-contrast enhanced apical view of the LV with an ill-
lateral wall toward the mid cavity. Contrast enhancement revea
consistent with non-compaction cardiomyopathy.Sonographers are then able to initiate some of the steps
required leading up to the actual administration of the
microbubble contrast agent.
The decision to proceed with contrast enhancement
should remain at the discretion of the attending physician
echocardiographer. The responsible physician may do this
following review on a case-by-case basis or there may be pre-
defined criteria agreed upon by medical staff and the labora-
tory director such that a timely and efficient sonographer-
driven protocol can be implemented.48 As an example, the
Mayo Clinic has a policy of starting with the apical views for
90e120 s to determine if endocardial border definition is
adequate with standard harmonic imaging or, if contrast is
required where the study is then undertaken using a contrast-
specific imaging protocol.49 Early recognition of the need for
contrast will streamline thewhole process and can potentially
allow the recommended 30 min monitoring requirement
following contrast administration to occur while the
remainder of the study is being performed.
3.3. Contrast administration
Once the indication has been established and screening for
the absence of allergies or contraindications has been
completed, informed consent from the patient must then be
obtained. This may be in the form of verbal or written consent
depending on the institutional policies.defined echodensity in the apex extending down along the
ls prominent trabeculae with deep intertrabecular recesses
Fig. 6 e Standard apical 4-chamber view demonstrating an extra-cardiac collection at the level of the mid-anterolateral wall.
Colour flow Doppler reveals a connection and flow between the LV cavity and the echo-free space. Contrast administration
confirms the presence of a narrow neck communicating with an extra-cardiac cavity consistent with an LV
pseudoaneurysm.
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performed according to the product information inserts.
Sonovue and Optison both require “activation” by hand
agitation while the vials of Definity are agitated for 45 s in the
VialMix device. The vials are then “vented” with an 18e21 G
needle and the contrast solution slowly drawn up with a
second needle and syringe to minimize microbubble
destruction. For resting transthoracic echocardiograms
ideally a 20 G intravenous cannulae is inserted into a larger
forearm or antecubital vein and a 3-way stopcock can be
attached. Boluses of contrast agent can then be injected
through the direct port in-linewith the vein and saline flushes
can then be given through the 90 sideport.50 Preferably, either
no connector line or if needed, a short tubing can be used. An
alternative site for cannulation will be required for treadmill
exercise stress echocardiograms that will not interfere with
the patient’s movements.
Contrast can be administered via either bolus or infusion
methods. The continuous infusion method offers the advan-
tages of extending the duration of LVO, providing a more
consistent oruniformcontrast effectwith reduction induration
of attenuation, and reducing the incidence of other artefacts
(swirling or blooming).51,52 These benefits would be extremely
useful for prolonged studies requiring multiple images, and
during stress echocardiography and MCE with quantitativeTable 2 e Contraindications for echocardiographic
contrast agents.
 Known hypersensitivity to the contrast agent or any of its com-
ponents (i.e. perflutren or blood products (Optison))
 Presence of intra-cardiac shunts (right-to-left, bi-directional or
transient right-to-left shunts)
 Pregnancy, lactation, severe hepatic diseases, and severe pul-
monary hypertensiona
 Intra-arterial injectionb
a The US FDA 2008 revised labelling for microbubble contrast
agents recommends aminimum 30-min period ofmonitoring post-
contrast administration to patients with severe pulmonary hy-
pertension or unstable cardiopulmonary conditions.
b Intra-arterial injection remains listed as a contraindication but
there are case reports of microbubble contrast agents being used to
guide alcohol septal ablation procedures.perfusion protocols.3 However, this approach requires the use
of infusion pumps, a period of dose or rate titration to achieve
the optimal contrast effect, and the constant need to manually
agitate the contrast syringe. Given the time consuming nature
(and cost implications) of such infusions the bolus approach is
the most widely used for resting LVO and for improving EBD in
rest and stress echocardiography.
The “diluted” bolus technique for LVO will be the focus of
the remainder of this review.47,53 Essentially the contents of
the vial of contrast (usually w1.3e1.5 mL) are withdrawn as
previously described and diluted with sterile normal saline to
10 mL in total. The initial bolus should be in the order of
1e2 mL followed by a slow flush of 5e10 mL of normal saline
to clear the line of any contrast agent. The flush is stopped
when contrast appears in the right ventricular cavity during
real-time imaging. Ideally, enough contrast solution should be
injected to achieve a uniformly bright LV cavity with the
darker appearingmyocardium. Usually the contrast effect will
persist for 15e30 s but this is dependent on the patient’s heart
rate and cardiac output. Repeat boluses are then administered
in individualized titrated doses of 0.5e1.0 mL with adjusted
flushes depending on the quality of contrast enhancement.
The bolus method is easy and practical and provides rapid
LVO but is limited by the relatively short duration of contrast
enhancement that requires repeated blousing. Therefore,
some variation in contrast intensity and more frequent arte-
facts throughout the study would be not unexpected. How-
ever, these can be easily addressedwith increasing experience
and maintaining good communication between the injector
and sonographer to optimize the timing of bolus delivery. This
is especially critical during stress echocardiogramswhere pre-
emptive contrast bolus injections are needed to minimize
delay between optimal LVO and image acquisition at the
various stages of stress.3.4. Instrumentation for contrast LVO and practical tips
for common pitfalls
Most commercial vendors of ultrasound equipment have
contrast-specific presets on their echocardiographymachines
that have greatly simplified the necessary system settings.
However, fine adjustment may still be required to optimally
reduce microbubble destruction, maximize persistence and
Table 3 e Example of an echocardiography laboratory
contrast setup and protocol for resting LVO.
Basic equipment
 Sterile syringes
 Sterile normal saline solutions
 Sterile large guage needles for venting and drawing up (21 G)
 Standard equipment required for intravenous cannulae inser-
tion (preferably 20 G) and maintenance of universal
precautions
 Three-way stopcock
 Fully-equipped resuscitation trolley (basic and advanced life
support)
 Appropriate facilities for post-administration monitoring where
indicated
 Refrigerator for storage of contrast vials
 Agitator (VialMix) for contrast agent “activation”
Patient identification
 Ideally sonographer-driven based on both clinical indication(s)
and technical difficulty of the study
 Early recognition of challenging studies based upon patient
characteristics, previous echocardiograms, or by screening with
apical views at start of the routine examination
 Notify attending physician of need for contrast, exclude contra-
indications, obtain consent (process based on local institutional
guidelines) and secure intravenous access
Contrast protocol
 Prepare or “activate” contrast agent as per product information:
B Contrast from a single vial (w1.3e1.5 mL) can be diluted to
10 mL in total with normal saline
 Instrument settings (use vendor contrast-specific presetswhere available):
B Harmonic imaging
B Reduce MI (Start with 0.2e0.4 to minimize microbubble
destruction)
B Increase receiver gains
B Adjust compression and dynamic range
B Optimize image to visualize the LV
B Move focus to level of the mitral annulus
 Contrast administration and image acquisition:
B “Diluted” bolus approach is easy to use and time-efficient
- 1e2 mL initial bolus followed by 5e10 mL of slow normal
saline flush
- Repeated titrated boluses of 0.5e1.0 mL administered as
required
B Image from apical windows first
- Orientate image using landmarks (e.g. ventricular or atrial
cavities or aortic root) or alternate between standard
harmonic and contrast-specific imaging presets
 Practical tips for common pitfalls:
B Far-field attenuation
- Wait for contrast to spontaneously dilute and clear
- Induce microbubble destruction by transiently increasing
MI
- Smaller subsequent boluses of contrast
B Swirling
- Increase dose or rate of bolus injections
- Decrease MI further
B Lateral rib artefact
- Move probe footprint
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resolution.
The basic default settings for contrast LVO should include:
- harmonic imaging (maximize frequency for best temporal
resolution at the expense of penetration),- reduced transmit power ormechanical index (MI, starting at
0.2e0.4 but can be decreased further to minimize micro-
bubble destruction), and
- increase receivergains to improvecontrastvisualization.50,54
The compression and dynamic range should be adjusted
(usually decreased) to amplify the “contrast” difference be-
tween the LV myocardium and blood pool. The image depth
should be reduced to “focus” on the LV and the focal zone
moved down to the level of the mitral annulus. The pre-
contrast image would appear as a dark or black LV cavity
with a faintly visible myocardium.
Thedepth canbedecreased further and the focal zoneplaced
at the level of the apex for focused imaging, where indicated.
Image orientation may become an issue as a result of this. The
usualanatomical landmarkssuchas theatrio-ventricularvalves
are difficult to visualize. Use of the ventricular cavities, the left
atrium, or aortic root may be more helpful in this instance or
transiently returning to standard harmonic imagingmodeas an
alternative (especially when switching between imaging
planes). Startingwith theapical four-chamberwindowisalways
best. Parasternal views can then be attempted after the apical
views have been acquired but the LV may be shadowed acous-
tically by contrast within the right ventricle in the near-field.
Optimal delivery of contrast (volume and rate) is essential and
the starting point has been outlined above. Images should be
acquiredatpeakcavityopacification (the imagesduring thefirst-
pass are very useful to obtain as near uniform opacification is
often achieved before far-field attenuation occurs).
Themain artefacts related to real-time 2D LVO imaging are
a) attenuation, b) swirling and c) rib artefacts.50,53,55
Attenuation occurs when there is a high concentration of
accumulated microbubbles in the apex that results in a signif-
icant amount of near-field backscatter and acoustic shadowing
of the far-field structures.Waiting for the contrast to dilute and
theattenuation to clear is a simple solution or as an alternative,
transiently increasing the MI to induce some degree of micro-
bubble destruction, can be used if image acquisition is time
critical. To avoid this problem a slower rate or smaller amount
of contrast bolus should be used for subsequent cycles. Swirling
is the “opposite” effect where there is inadequate opacification
of the LV cavity with the contrast agent. The principal reasons
for this are inadequate amount of contrast injected, often in the
setting of poor LV systolic function, or excessive amount of
microbubbledestruction. Increasing thedoseor rate of contrast
administration and the saline flush and/or further reducing the
MI will mitigate this effect. Increasing the overall gains or
adjusting the vertical and horizontal time-gain compensations
can also improve a “dim” contrast effect. The lateral artifact on
the apical four-chamber view results from adjacent ribs
obstructing the transmissionofultrasoundfromthetransducer
in the lateral scan planes and thereby obscuring the lateral
segments. Contrast opacification does not occur as insonating
sound waves are required to resonate the microbubbles and
produce the returning harmonic signals. Moving the probe
footprint to adjust the image orientation will usually compen-
sate for this artefact.
Finally, when microbubble contrast agents are used for
enhancementofspectralDopplersignals, significant“blooming”
can occur from the strong acoustic backscatter. Only small
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purpose and a similar approach of timely waiting for sponta-
neous dilution and dissipation or reducing the Doppler gain can
help minimize this problem.4. Safety and contraindications
There is no debate that the use of microbubble ultrasound
contrast in echocardiography is safe and beneficial where
indicated. Chronologically, post-marketing reports of four
deaths and nearly two hundred other serious cardiopulmo-
nary reactions during or within 30 min of the administration
of Definity contrast resulted in the revision of labelling and a
black box warning issued by the Food and Drug Administra-
tion (FDA) released in October 2007.56 Perflutren-based agents
were contraindicated for use in A) the setting of acute coro-
nary syndromes, B) acute myocardial infarction and C) un-
stable heart failure.
Despite the temporal relationship, there was no clear
causative effect established, and these fatalities were more
likely related to the underlying disease states. Nonetheless,
the recommendation was made to have patients undergo
monitoring (vitals and electrocardiography) during and for
30 min after the contrast injection. This had significant time-
efficiency implications in busy echocardiography laboratories.
Following on from this, large retrospective studies and a large
meta-analysis have repeatedly published the absence of any
statistically significant difference in mortality between pa-
tients who underwent contrast-enhanced and non-contrast
echocardiographic examinations despite the higher level of
clinical acuity and co-morbidities in those patients requiring
contrast administration.57e59 The same safety profile has been
confirmed with stress echocardiography as well.60 In July
2008, the black box warning (for Definity and Optison) was
revised and the 30minmonitoring requirementwas limited to
patients with pulmonary hypertension (no clear definition of
severity provided) or unstable cardiopulmonary conditions.
Post-marketing surveillance of Definity has estimated the
risk of a serious adverse cardiopulmonary event to be in the
order of 1 in 10,0000 e usually the result of an anaphylactoid
reaction or a complement activation-related pseudoallergy.61
These can usually be managed with antihistamines, intrave-
nous fluids, and/or intramuscular adrenaline (0.3 mg of 1:1000
dilution of adrenaline) depending on the severity of the reac-
tion. Common, albeit infrequent (<2.1%) reported side effects
from clinical trials have included headaches, flushing, back
pain, nausea, vomiting, dizziness, chest pain, taste perversion
and injection site reactions.16 These are often mild, self-
limiting and may be managed symptomatically.
Current widely accepted contraindications are a known
hypersensitivity to the contrast agent or any of its compo-
nents (including blood products in the case of Optison) and
intra-cardiac shunts (right-to-left, bi-directional or transient
right-to-left shunts) (Table 2). Other contraindications include
pregnancy, lactation, severe pulmonary hypertension, and
severe hepatic diseases. Intra-arterial or intra-coronary in-
jections of contrast have been used during alcohol septal
ablation procedures for hypertrophic cardiomyopathy but are
not currently approved per se. Any adverse reaction should bedocumented in the study report for future reference and
highlighted for serial studies.5. Cost-effectiveness
Owing to improved diagnostic power, accuracy and confidence,
the use of microbubble contrast enhancement offers the po-
tential of cost savings by reducing the need for further down-
stream testing and therefore also avoiding the risks associated
with more invasive investigations. Shaw et al elegantly
demonstrated the increased proportion of non-diagnostic
studies in the non-contrast patients paralleled a 42% need for
repeat confirmatory testing as compared with 12% when
contrast was used (p < 0.0001).62 Although the upfront cost was
higher with contrast use, there was a 17e70% reduction in
further investigations, 2.7 fold higher diagnostic accuracy and a
savings of $269 per patient. Along very similar lines, but in the
stress echocardiography population, Thanigaraj and colleagues
integrated the costs of additional nuclear testing for non-
contrast non-diagnostic stress echocardiograms and found a
furtherfinancial savingsof $238perpatient (including thecostof
the contrast agent).63 In the critically ill setting where patients
are most likely to derive the greatest technical benefit from
contrast use, the cost-effective ratio of contrast enhancement
for theassessmentofLVEFresultedina$423savings forevery1%
increase in diagnostic accuracy per 100 patients.646. Conclusion
Microbubble contrast enhancement is an essential technique
for any echocardiography laboratory in the modern era.
Currently approved indications include LVO for delineation of
LV structural abnormalities, improvement of EBD (during
resting and stress echocardiography), and quantification of
LVEF. Contrast enhancement has been demonstrated to
improve the diagnostic accuracy, readers’ confidence, and
reproducibility for all of these categories. Contrast imaging
protocols can be incorporated in a time-efficient manner into
busy echocardiography laboratories and may have significant
cost savings by reducing the number of non-diagnostic studies
requiring further downstream testing. Microbubble contrast
agents now have a proven safety track record and training in
contrast-specific imaging techniques can be easily acquired by
credentialed sonographersandaccreditedechocardiographers.Conflicts of interest
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